Phaseline

Companies › Suzhou Teligene

Suzhou Teligene: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TL938
HER2 inhibitor
–Phase 2Colorectal Cancer MetastaticOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06589830TL938Phase 2Colorectal Cancer MetastaticOncologyOct 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.